These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 34280680)

  • 21. Use of corticosteroids in multiple sclerosis by consultant neurologists in the United Kingdom.
    Tremlett HL; Luscombe DK; Wiles CM
    J Neurol Neurosurg Psychiatry; 1998 Sep; 65(3):362-5. PubMed ID: 9728950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis.
    Burton JM; O'Connor PW; Hohol M; Beyene J
    Cochrane Database Syst Rev; 2009 Jul; (3):CD006921. PubMed ID: 19588409
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Beneficial effects of intravenous immunoglobulin as an add-on therapy to azathioprine for NMO-IgG-seropositive neuromyelitis optica spectrum disorders.
    Lim YM; Kim H; Lee EJ; Kim HW; Kim HJ; Kim KK
    Mult Scler Relat Disord; 2020 Jul; 42():102109. PubMed ID: 32387973
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment Patterns and Relapses Among Newly Treated Multiple Sclerosis Patients From a Retrospective Claims Analysis.
    Kantor D; Mehta R; Pelletier C; Tian M; Noxon V; Johnson BH; Bonafede M
    Clin Ther; 2020 Nov; 42(11):2136-2147.e3. PubMed ID: 33160682
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravenous immunoglobulin as the rescue treatment in NMOSD patients.
    Lin J; Xue B; Zhu R; Pan J; Li J; Lin Y; Li X; Xia J
    Neurol Sci; 2021 Sep; 42(9):3857-3863. PubMed ID: 33523317
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic.
    Brownlee W; Bourdette D; Broadley S; Killestein J; Ciccarelli O
    Neurology; 2020 Jun; 94(22):949-952. PubMed ID: 32241953
    [No Abstract]   [Full Text] [Related]  

  • 27. [Neuromyelitis optica].
    Nakashima I
    Rinsho Shinkeigaku; 2012; 52(11):1231-3. PubMed ID: 23196573
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pulse immunosuppressive therapy for multiple sclerosis during the SARS-CoV-2 lockdown de-escalation plan: Safety algorithm.
    Valero-López G; Carreón-Guarnizo E; Hernández-Clares R; Iniesta-Martínez F; Jiménez-Veiga J; Moreno-Docon A; Iborra-Bendicho MA; Aznar-Robles E; Hellín-Gil MF; Morales-Ortiz A; Meca-Lallana JE
    Neurologia (Engl Ed); 2020; 35(6):357-362. PubMed ID: 32591152
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Similar biological effect of high-dose oral versus intravenous methylprednisolone in multiple sclerosis relapses.
    Grau-López L; Teniente-Serra A; Tintoré M; Rovira A; Ramió-Torrenta L; Brieva L; Saiz A; Cano A; Carmona O; Hervás JV; Martínez-Cáceres EM; Ramo-Tello C
    Mult Scler; 2015 Apr; 21(5):646-50. PubMed ID: 25145693
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.
    Tahara M; Oeda T; Okada K; Kiriyama T; Ochi K; Maruyama H; Fukaura H; Nomura K; Shimizu Y; Mori M; Nakashima I; Misu T; Umemura A; Yamamoto K; Sawada H
    Lancet Neurol; 2020 Apr; 19(4):298-306. PubMed ID: 32199095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial.
    Zhang C; Zhang M; Qiu W; Ma H; Zhang X; Zhu Z; Yang CS; Jia D; Zhang TX; Yuan M; Feng Y; Yang L; Lu W; Yu C; Bennett JL; Shi FD;
    Lancet Neurol; 2020 May; 19(5):391-401. PubMed ID: 32333897
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral or intravenous methylprednisolone for acute relapses of MS?
    Barkhof F; Polman C
    Lancet; 1997 Mar; 349(9056):893-4. PubMed ID: 9093245
    [No Abstract]   [Full Text] [Related]  

  • 33. New relapse of multiple sclerosis and neuromyelitis optica as a potential adverse event of AstraZeneca AZD1222 vaccination for COVID-19.
    Fragoso YD; Gomes S; Gonçalves MVM; Mendes Junior E; Oliveira BES; Rocha CF; Santos GACD; Tauil CB; Araujo RV; Peron JPS
    Mult Scler Relat Disord; 2022 Jan; 57():103321. PubMed ID: 35158439
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies.
    Giovannoni G; Gold R; Fox RJ; Kappos L; Kita M; Yang M; Sarda SP; Zhang R; Viglietta V; Havrdova E
    Clin Ther; 2015 Nov; 37(11):2543-51. PubMed ID: 26526385
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-utility of oral methylprednisolone in the treatment of multiple sclerosis relapses: Results from the COPOUSEP trial.
    Michel M; Le Page E; Laplaud DA; Wardi R; Lebrun C; Zagnoli F; Wiertlewski S; Coustans M; Edan G; Chevreul K; Veillard D; ;
    Rev Neurol (Paris); 2022 Mar; 178(3):241-248. PubMed ID: 34598781
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange.
    Abboud H; Petrak A; Mealy M; Sasidharan S; Siddique L; Levy M
    Mult Scler; 2016 Feb; 22(2):185-92. PubMed ID: 25921047
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influences of pregnancy on neuromyelitis optica spectrum disorders and multiple sclerosis.
    Tong Y; Liu J; Yang T; Kang Y; Wang J; Zhao T; Cheng C; Fan Y
    Mult Scler Relat Disord; 2018 Oct; 25():61-65. PubMed ID: 30048918
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Tryptophan immunoadsorption for multiple sclerosis and neuromyelitis optica: therapy option for acute relapses during pregnancy and breastfeeding].
    Hoffmann F; Kraft A; Heigl F; Mauch E; Koehler J; Harms L; Kümpfel T; Köhler W; Klingel R; Fassbender C; Schimrigk S
    Nervenarzt; 2015 Feb; 86(2):179-86. PubMed ID: 25604838
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk of venous thromboembolism in neuromyelitis optica patients hospitalized for acute relapse.
    Farber RS; Gross R; Zakin E; Fabian M
    Mult Scler; 2017 Jun; 23(7):988-994. PubMed ID: 27672136
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment of Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder and Myasthenia Gravis during the COVID-19 Pandemic].
    Nakamura M; Nakashima I
    Brain Nerve; 2020 Oct; 72(10):1079-1083. PubMed ID: 33051396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.